Rhythm Biosciences (ASX: RHY): Interview with CEO David Atkins

Rhythm Biosciences (ASX:RHY) We spoke to Dr. David Atkins, CEO of Rhythm Biosciences (ASX: RHY), about…

AFT Pharmaceuticals (ASX:AFP) at the Pitt Street Research Life Sciences Conference 2024

AFT Pharmaceuticals (ASX:AFP) AFT Pharmaceuticals (ASX:AFP) CEO Dr. Harley Atkinson presented at the Pitt Street Research…

Island Pharmaceuticals (ASX:ILA) spoke at the Pitt Street Research Life Sciences Conference 2024

Island Pharmaceuticals (ASX:ILA) Island Pharmaceuticals (ASX:ILA) Executive Chairman Dr. Paul MacLeman spoke at the Pitt Street…

Cann Group (ASX:CAN) at the Pitt Street Research Life Sciences Conference 2024

Cann Group (ASX:CAN) Cann Group (ASX:CAN) Jenni Pilcher spoke at the Pitt Street Research Life Sciences…

Actinogen (ASX:ACW) presented at the Pitt Street Research Life Science Conference 2024

Actinogen (ASX:ACW) Dr. Steve Gourlay, MD & CEO of Actinogen (ASX:ACW), presented at the Pitt Street…

Graphite play Black Rock Mining (ASX:BKT) has got its ducks in a row in 2024

Black Rock Mining (ASX:BKT) We spoke with John de Vries, CEO of Black Rock Mining (ASX:…

Invion (ASX:IVX) at the Pitt Street Research Life Sciences Conference 2024

Invion (ASX:IVX) Thian Chew, Executive Chair and CEO of Invion (ASX:IVX), presented at the Pitt Street…

Percheron Therapeutics (ASX:PER) presented at the Pitt Street Research Life Sciences Conference 2024

Percheron Therapeutics (ASX:PER) Dr James Garner, MD & CEO of Percheron Therapeutics (ASX:PER), presented at the…

Proteomics International Laboratories (ASX:PIQ) presenting at the Pitt Street Research Life Sciences Conference 2024

Proteomics International Laboratories Proteomics International Laboratories‘ (ASX:PIQ) MD, Dr Richard Lipscombe, spoke at the Pitt Street…

MTM Critical Metals (ASX: MTM) is going places! Interview with CEO Michael Walshe

MTM Critical Metals is going places! We spoke to Michael Walshe, CEO of MTM Critical Metals…

Archer Materials (ASX:AXE) R&D is on track to deliver great things!

Archer Materials is tracking well with the development of the Biochip and 12CQ We spoke with…

Weebit Nano (ASX:WBT) is on track for more commercial deals in 2024

  Weebit Nano (ASX:WBT) We spoke with Weebit Nano CEO, Coby Hanoch, about the A$1m in…

Actinogen Medical (ASX:ACW): Interview with CEO Dr Steve Gourlay

Actinogen Medical We talked with Dr Steve Gourlay, the CEO of Actinogen Medical (ASX:ACW), about the…

Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals

  Chimeric Therapeutics (ASX:CHM) We spoke to Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics…

BrainChip (ASX:BRN): Post AGM interview with CEO Sean Hehir

Interview with Sean Hehir, CEO of BrainChip (ASX:BRN) We spoke with Sean Hehir, CEO of BrainChip…

GreenHy2 (ASX: H2G): Interview with Managing Director Dr. Paul Dalgleish, Managing Director

GreenHy2 (ASX: H2G) We spoke to Dr. Paul Dalgleish, CEO of GreenHy2 (ASX:H2G), about the company’s…

WhiteHawk (ASX:WHK): Many opportunities in Cyber Security for the taking

WhiteHawk (ASX:WHK) We spoke with Terry Roberts, CEO of Cyber Security company WhiteHawk (ASX:WHK), about the…

Transition Resources (Pre IPO): Interview with MD David Wilson

Transition Resources We spoke to David Wilson, Managing Director of the privately held Transition Resources, about…